SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — John Locke

PatientJohn Locke
Date of birth1966-09-08
IdentifiersMRN HR-EN001-SYN; SSN (made up) 000-01-8305
Document date2026-06-18
AuthorPrudence Hartwell-Osei, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Twelve-week asthma review with repeat spirometry. [S]

History of Present Illness

Mr. Locke returns twelve weeks after starting budesonide-formoterol as maintenance and reliever. He finished the eight-week pulmonary rehabilitation program, attending all 16 sessions, and walks 30 minutes five days a week. He needs three or four extra inhalations a week, mostly after his days in the city, and woke at night with cough once in the past month. He has had no flare and no oral corticosteroids. The dose counter matches his diary, with about one missed evening dose a fortnight. He has had no hoarseness or sore mouth. His home peak flow is best at 440 L/min in the mornings and falls to about 360 after a city day. The open fires stay out; a small air monitor in his study usually reads below 10 ug/m3 of PM2.5. He has spent two or three days a month in the city and stayed away during an air quality alert in May. [S]

ElementDetail
Reliever useThree or four extra inhalations a week
Night wakingOnce in the past month
AdherenceAbout one missed maintenance dose a fortnight; dose counter agrees
Rehabilitation16 of 16 sessions completed
Peak flowPersonal best 440 L/min
Asthma Control Test19, up from 13

Review of Systems

SystemResultFinding
RespiratoryPositiveBreathless on steep hills; some cough and tightness after city days; no hemoptysis
Ears, nose, mouth, and throatNegativeNo hoarseness, sore mouth, or thrush
CardiovascularNegativeNo palpitations, tremor, or ankle swelling

3 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Albuterol 90 mcg/actuation inhaler, two puffs every 4 hours as needed while tests are done; hold for 6 hours before spirometryTwo puffs every 4 hours as neededRespiratory tract route2026-03-12 to 2026-03-26completedS
Budesonide-formoterol 160/4.5 mcg inhaler as maintenance and reliever (GINA track 1, step 4): two inhalations twice daily and one inhalation as needed for symptoms, no more than 12 inhalations a dayTwo inhalations twice daily plus one as needed; no more than 12 a dayRespiratory tract route2026-03-26activeS
Tiotropium 2.5 mcg/actuation soft-mist inhaler, two inhalations once daily (add-on long-acting muscarinic antagonist, GINA step 5)Two inhalations once a dayRespiratory tract route2026-06-18activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-06-18Body height178cmS
2026-06-18Body weight62.8kgS
2026-06-18Body mass index (BMI) [Ratio]19.8kg/m2S
2026-06-18Systolic blood pressure118mm[Hg]S
2026-06-18Diastolic blood pressure72mm[Hg]S
2026-06-18Heart rate76/minS
2026-06-18Respiratory rate16/minS
2026-06-18Body temperature36.6CelS
2026-06-18Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-06-18Total score [ACT]19{score}S
2026-06-18FEV1 --pre bronchodilation2.46LLower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cm; predicted 3.38 LLowS
2026-06-18FEV1 measured/predicted73%GLI Global race-neutral equations for a man of 59, 178 cmLowS
2026-06-18FEV1 --post bronchodilation2.58LLower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cm; predicted 3.38 LLowS
2026-06-18Forced vital capacity [Volume] Respiratory system --post bronchodilation4.12LLower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cm; predicted 4.37 LNormalS
2026-06-18FEV1/FVC --post bronchodilation0.63{ratio}Lower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cm; below it (and below 0.70) after bronchodilator means persistent airflow limitationLowS
2026-06-18Fractional concentration of exhaled nitric oxide22[ppb]In adults, below 25 ppb low, 25 to 50 intermediate, above 50 high (ATS)NormalS
2026-06-18Six minute walk test505mPredicted about 630 m for his age, sex, height and weight (Enright and Sherrill); lower limit about 480 mNormalS

Physical Exam

Vital signs recorded on 2026-06-18; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 62.8 kg
MouthNo oral candidiasis
RespiratoryGood air entry; a few end-expiratory wheezes on forced expiration; oxygen saturation 97 percent

Problems

ProblemClinical statusVerificationCodeProvenance
Chronic cough with wheeze and breathlessness since his late thirties, worse every winter and within a day of any stay in the city or by an open fire, better in warm weather and country air; night cough two or three times a week this winter; under evaluationresolvedconfirmed R05.3S — Synthetic presenting problem echoing his documented lifelong cough and breathlessness in London's coal smoke; superseded by the diagnosis at the second visit.
Long exposure to urban air pollution (decades in a large city with heavy traffic and coal and wood burning) and to indoor solid-fuel smoke from open coal and wood fires at homeactiveconfirmed Z77.110S — Synthetic modern exposure echoing the coal smoke that he, Sydenham, and Lady Masham blamed for his cough; no historical level of exposure is asserted.
Asthma with persistent airflow limitation, type 2 (eosinophilic) phenotype, in a never-smoker: post-bronchodilator FEV1/FVC 0.62, FEV1 62 percent predicted rising 380 mL after albuterol, FeNO 41 ppb, eosinophils 0.46 x 10^3/uL, IgE 186 IU/mL, normal DLCO, no emphysema on CT; aggravated by air pollution and indoor smoke; not COPDactiveconfirmed J45.40S — Synthetic modern diagnosis. His lifelong cough and breathlessness worse in coal smoke are documented (D); calling them asthma is a modern retrospective reading (R).

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
SurveyAsthma Control TestEvery visitCompleted today19, up from 13; not yet well controlled (20 or more)
ImagingSpirometry before and after bronchodilatorAt diagnosis, 3 to 6 months after starting treatment, then every 1 to 2 yearsCompleted todayFEV1 2.46 L before (73 percent predicted) and 2.58 L after bronchodilator; FVC 4.12 L after; FEV1/FVC 0.63 after, still below the lower limit of normal; next in one to two years
ImagingFeNOTo monitor inhaled-corticosteroid responseCompleted today22 ppb, down from 41
ImagingSix-minute walk testBefore and after pulmonary rehabilitationCompleted today505 m, up 75 m from 430 m
ImagingHome peak expiratory flowDaily for moderate to severe asthma, then with symptomsCompleted todayDiary reviewed: personal best 440 L/min; about 360 after city days
ExaminationInhaler technique with his own devicesEvery visitCompleted todayBudesonide-formoterol technique correct; tiotropium soft-mist inhaler taught today, correct by teach-back
Medication safetyAdherence and reliever useEvery visitCompleted todayAbout one missed maintenance dose a fortnight by dose counter and diary; three or four as-needed inhalations a week
Medication safetyInhaled-corticosteroid side effects (hoarseness, thrush)Every visitCompleted todayNone
SurveyExacerbation historyEvery visitCompleted todayNone since treatment began; no oral corticosteroids
Self-managementTrigger and exposure review: indoor solid-fuel smoke, outdoor air pollution and air quality alerts, tobacco and vaping, occupational exposures, allergensEvery visitCompleted todayOpen fires out of use; indoor PM2.5 on his monitor usually below 10 ug/m3; HEPA air cleaners running; city trip postponed during an air quality alert
Self-managementSmoking and vaping statusEvery visitCompleted todayNever smoker; no vaping; no secondhand smoke
Self-managementWritten asthma action planEvery visit and after every flareCompleted todayUpdated with peak-flow zones: green 352 or more, yellow 220 to 351, red below 220 L/min
Medication safetyStep-up and step-down assessmentEvery visitCompleted todayNot well controlled on step 4 with good adherence and technique: step up by adding tiotropium (step 5)
ReferralPulmonary rehabilitationFor persistent breathlessness or reduced exercise capacityCompleted todayProgram completed; home walking program to maintain the gain
Self-managementVaccination statusYearlyUp to datePCV20 given at the diagnosis visit; influenza, COVID-19, and RSV vaccines due in the autumn
Medication safetyBiologic candidacyWhen asthma is severe and uncontrolled despite optimized step 4 to 5 treatment with confirmed adherence and techniqueNot indicatedNo exacerbations needing oral corticosteroids and not uncontrolled on optimized treatment

Goal progress:

Guideline basis: CMID: Clinical Monitoring Intelligence Database, asthma and COPD monographs (2026); Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020); Stanojevic S, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J 2022;60(1):2101499 (PMID 34949706) (2022); Bhakta NR, et al. Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement. Am J Respir Crit Care Med 2023;207(8):978-995 (PMID 36973004) (2023); Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline (2023); WHO global air quality guidelines: particulate matter (PM2.5 and PM10), ozone, nitrogen dioxide, sulfur dioxide and carbon monoxide (2021); Carlsten C, et al. Personal strategies to minimise effects of air pollution on respiratory health: advice for providers, patients and the public. Eur Respir J 2020;55(6):1902056 (PMID 32241830) (2020); AQI Basics (2026); Adult Immunization Schedule by Age (2026)

Follow-up: Preventive visit in three months, with a brief asthma check; asthma review with an Asthma Control Test in four months. Next scheduled visit 2026-09-17: preventive health visit at 60. [S]